Genetic and molecular profilingof human cancers may in the future enable selection of a tumor subtypesusceptible to PPARγ agonists, as specific genotypes and patternsof nuclear receptor and cofactor expression might predict resistance orresponsiveness to PPARγ signal transduction. This evidence concerns the gene PPARG and neoplasm.